Showing 161 - 180 results of 408 for search '"HPV"', query time: 0.13s Refine Results
  1. 161
  2. 162
  3. 163
  4. 164
  5. 165
  6. 166
  7. 167
  8. 168
  9. 169
  10. 170
  11. 171

    Performance of HPV E4 and p16INK4a biomarkers in predicting regression of cervical intraepithelial neoplasia grade 2 (CIN2): protocol for a historical cohort study by David Jenkins, Mark H Stoler, Anne Hammer, Torben Steiniche, Lone Kjeld Petersen, Patti E Gravitt, Rikke Kamp Damgaard, Maurits NC de Koning, Wim GV Quint, John Doorbar, Johnny Kahlert

    Published 2022-07-01
    “…The combination of the novel biomarker human papillomavirus (HPV) E4 with p16INK4a targets steps in the transition from a productive oncogenic HPV infection (CIN1) to a transformed lesion (CIN3) within CIN2. …”
    Get full text
    Article
  12. 172
  13. 173
  14. 174
  15. 175
  16. 176
  17. 177

    Safety and efficacy of the therapeutic DNA-based vaccine VB10.16 in combination with atezolizumab in persistent, recurrent or metastatic HPV16-positive cervical cancer: a multicenter, single-arm phase 2a study by Hannelore Denys, Frederik Marmé, Frederic Forget, Lukas Rob, Pawel Blecharz, Kristina Lindemann, Peter Hillemanns, Linn Wölber, Theresa Link, Jean-Francois Baurain, Mariusz Bidziński, Linn Woelber, Michal ZikÁN, Josef Chovanec, Christian Dannecker, Stéphanie Henry, Hannelore G Denys, Velko Minchev, Anders Rosholm, Kaja C G Berg, Roberto S Oliveri, Marchela Koleva, Bozhil Robev

    Published 2025-01-01
    “…We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the immune checkpoint inhibitor atezolizumab in patients with human papillomavirus (HPV)16-positive r/m cervical cancer.Patients and methods This multicenter, single-arm, phase 2a study (NCT04405349, registered 26 May 2020) enrolled adult patients with persistent, r/m HPV16-positive cervical cancer. …”
    Get full text
    Article
  18. 178

    Limitations on the Detection Rate of High-Risk HPV by Hybrid Capture 2 Methodology in High Grade Intraepithelial (HSIL) or Atypical Squamous Cells-Cannot Exclude HSIL (ASC-H) Cytological Lesions with Proved CIN2+ by Jean-Christophe Noël, Philippe Simon

    Published 2015-01-01
    “…These data although they are infrequent must be clearly referred before to start an HPV primary screening of CIN2+ especially with HCII methodology.…”
    Get full text
    Article
  19. 179
  20. 180